GABAA Receptor-Mediated Acceleration of Aging-Associated Memory Decline in APP/PS1 Mice and Its Pharmacological Treatment by Picrotoxin
Open Access
- 21 August 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (8), e3029
- https://doi.org/10.1371/journal.pone.0003029
Abstract
Advanced age and mutations in the genes encoding amyloid precursor protein (APP) and presenilin (PS1) are two serious risk factors for Alzheimer's disease (AD). Finding common pathogenic changes originating from these risks may lead to a new therapeutic strategy. We observed a decline in memory performance and reduction in hippocampal long-term potentiation (LTP) in both mature adult (9–15 months) transgenic APP/PS1 mice and old (19–25 months) non-transgenic (nonTg) mice. By contrast, in the presence of bicuculline, a GABAA receptor antagonist, LTP in adult APP/PS1 mice and old nonTg mice was larger than that in adult nonTg mice. The increased LTP levels in bicuculline-treated slices suggested that GABAA receptor-mediated inhibition in adult APP/PS1 and old nonTg mice was upregulated. Assuming that enhanced inhibition of LTP mediates memory decline in APP/PS1 mice, we rescued memory deficits in adult APP/PS1 mice by treating them with another GABAA receptor antagonist, picrotoxin (PTX), at a non-epileptic dose for 10 days. Among the saline vehicle-treated groups, substantially higher levels of synaptic proteins such as GABAA receptor α1 subunit, PSD95, and NR2B were observed in APP/PS1 mice than in nonTg control mice. This difference was insignificant among PTX-treated groups, suggesting that memory decline in APP/PS1 mice may result from changes in synaptic protein levels through homeostatic mechanisms. Several independent studies reported previously in aged rodents both an increased level of GABAA receptor α1 subunit and improvement of cognitive functions by long term GABAA receptor antagonist treatment. Therefore, reduced LTP linked to enhanced GABAA receptor-mediated inhibition may be triggered by aging and may be accelerated by familial AD-linked gene products like Aβ and mutant PS1, leading to cognitive decline that is pharmacologically treatable at least at this stage of disease progression in mice.Keywords
This publication has 49 references indexed in Scilit:
- Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tauThe EMBO Journal, 2007
- Regulation of NMDA receptors by phosphorylationNeuropharmacology, 2007
- Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I‐CT100 transgenic mice, an Alzheimer's disease modelThe FASEB Journal, 2006
- NMDA receptor–independent long-term depression correlates with successful aging in ratsNature Neuroscience, 2005
- Environmental Enrichment Mitigates Cognitive Deficits in a Mouse Model of Alzheimer's DiseaseJournal of Neuroscience, 2005
- Long-term potentiation and the ageing brainPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2003
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003
- Increase in Single L-Type Calcium Channels in Hippocampal Neurons During AgingScience, 1996
- The Ability of Amyloid β‐Protein [AβP (1–40)] to Form Ca2+ Channels Provides a Mechanism for Neuronal Death in Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 1994
- Severity of spatial learning impairment in aging: Development of a learning index for performance in the Morris water maze.Behavioral Neuroscience, 1993